These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31530036)

  • 1. Management of relapsing-remitting multiple sclerosis in Qatar: an expert consensus.
    Deleu D; Canibaño B; Mesraoua B; Adeli G; Abdelmoneim MS; Ali Y; Elalamy O; Melikyan G; Boshra A
    Curr Med Res Opin; 2020 Feb; 36(2):251-260. PubMed ID: 31530036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Ingwersen J; Aktas O; Hartung HP
    Neurotherapeutics; 2016 Jan; 13(1):47-57. PubMed ID: 26701666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
    Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
    Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
    Wiebenga OT; Schoonheim MM; Hulst HE; Nagtegaal GJ; Strijbis EM; Steenwijk MD; Polman CH; Pouwels PJ; Barkhof F; Geurts JJ
    AJNR Am J Neuroradiol; 2016 Jun; 37(6):1030-7. PubMed ID: 26965463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future trends in multiple sclerosis management: Near East perspective.
    Hatem A; El Ayoubi NK; Habahbeh M; Ghanim Z; Al-Naqshbandi M; Raki A; Joudi H; Sahraian MA
    Mult Scler Relat Disord; 2023 Aug; 76():104800. PubMed ID: 37307691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
    Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.
    Landmeyer NC; Bürkner PC; Wiendl H; Ruck T; Hartung HP; Holling H; Meuth SG; Johnen A
    Neurology; 2020 Jun; 94(22):e2373-e2383. PubMed ID: 32430312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
    Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
    Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of dimethyl fumarate as first line therapy in MS patients - one center real life observation study.
    Sałacińska D; Pogoda A; Żółkiewicz J; Stępień A
    Pol Merkur Lekarski; 2019 Dec; 47(282):221-225. PubMed ID: 31945023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
    Kapica-Topczewska K; Tarasiuk J; Collin F; Brola W; Chorąży M; Czarnowska A; Kwaśniewski M; Bartosik-Psujek H; Adamczyk-Sowa M; Kochanowicz J; Kułakowska A
    PLoS One; 2019; 14(10):e0223863. PubMed ID: 31647829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.
    Deleu D; Mesraoua B; El Khider H; Canibano B; Melikyan G; Al Hail H; Mhjob N; Bhagat A; Ibrahim F; Hanssens Y
    Curr Med Res Opin; 2017 Mar; 33(3):439-458. PubMed ID: 27892723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on disease-modifying treatments for multiple sclerosis.
    Carrithers MD
    Clin Ther; 2014 Dec; 36(12):1938-1945. PubMed ID: 25218310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.